SGLT2 inhibitors: A groundbreaking class of cardiovascular drugs, but who benefits most?

被引：0
|
作者：
Koufakis, Theocharis [1 ]
Popovic, Djordje S. [2 ,3 ]
Maltese, Giuseppe [4 ,5 ]
Papanas, Nikolaos [6 ]
机构：
[1] Aristotle Univ Thessaloniki, Hippokration Gen Hosp, Propedeut Dept Internal Med 2, Thessaloniki 54642, Greece
[2] Clin Ctr Vojvodina, Clin Endocrinol Diabet & Metab Disorders, Novi Sad, Serbia
[3] Univ Novi Sad, Med Fac, Novi Sad, Serbia
[4] Epsom & St Helier Univ Hosp, Dept Diabet & Endocrinol, Sutton SM5 1AA, Surrey, England
[5] Kings Coll London, Fac Life Sci & Med, Cardiovasc Div, Unit Metab Med, London WC2R 2LS, England
[6] Democritus Univ Thrace, Univ Hosp Alexandroupolis, Diabet Ctr, Dept Internal Med 2, Alexandroupolis, Greece
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2024年 / 412卷
关键词：
SGLT2; inhibitors; Heart failure; Myocardial infarction; Nt-proBNP;
D O I：
10.1016/j.ijcard.2024.132326
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
    Marc Evans
    Debbie Hicks
    Dipesh Patel
    Vinod Patel
    Phil McEwan
    Umesh Dashora
    Diabetes Therapy, 2020, 11 : 37 - 52
  • [42] Cardiorenal effects of SGLT2 inhibitors: who might benefit?
    Klug, E.
    Rayner, B.
    Wasserfall, M.
    Kok, A.
    Mpe, M.
    Ruder, S.
    Mohamed, N. A.
    Webb, D.
    JOURNAL OF ENDOCRINOLOGY METABOLISM AND DIABETES OF SOUTH AFRICA, 2024, 29 (01) : 8 - 17
  • [43] The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors
    Cangoz, S.
    Chang, Y. -Y.
    Chempakaseril, S. J.
    Guduru, R. C.
    Huynh, L. M.
    John, J. S.
    John, S. T.
    Joseph, M. E.
    Judge, R.
    Kimmey, R.
    Kudratov, K.
    Lee, P. J.
    Madhani, I. C.
    Shim, P. J.
    Singh, S.
    Singh, S.
    Ruchalski, C.
    Raffa, R. B.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2013, 38 (05) : 350 - 359
  • [44] SGLT2 Inhibitors: A Comparison of Cardiovascular, Medical, and Cost Outcomes
    Schwab, Phil
    Bowe, Andy
    Tindal, Michael
    Meah, Yunus A.
    Poonawalla, Insiya
    DIABETES, 2020, 69
  • [45] SGLT2 Inhibitors as the Backbone of Therapy for Cardiovascular and Renal Protection
    Felice Gragnano
    Fabrizia Terracciano
    Paolo Calabrò
    Journal of Cardiovascular Translational Research, 2024, 17 : 227 - 229
  • [46] The effect of SGLT2 inhibitors on cardiovascular events and renal function
    Imprialos, Konstantinos P.
    Stavropoulos, Konstantinos
    Doumas, Michael
    Karagiannis, Asterios
    Athyros, Vasilios G.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (11) : 1251 - 1261
  • [47] Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
    Abdullah Kaplan
    Emna Abidi
    Ahmed El-Yazbi
    Ali Eid
    George W. Booz
    Fouad A. Zouein
    Heart Failure Reviews, 2018, 23 : 419 - 437
  • [48] SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice
    Ali, Amar
    Bain, Steve
    Hicks, Debbie
    Jones, Phillip Newland
    Patel, Dipesh C.
    Evans, Marc
    Fernando, Kevin
    James, June
    Milne, Nicola
    Viljoen, Adie
    Wilding, John
    DIABETES THERAPY, 2019, 10 (05) : 1595 - 1622
  • [49] Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases
    Pan, Runfang
    He, Yuqing
    Melisandre, Wan
    Zhang, Yunyi
    Su, Wenyuan
    Feng, Jiaming
    Jia, Chengyao
    Li, Shaoling
    Liu, Baonian
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [50] SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
    Amar Ali
    Steve Bain
    Debbie Hicks
    Phillip Newland Jones
    Dipesh C. Patel
    Marc Evans
    Kevin Fernando
    June James
    Nicola Milne
    Adie Viljoen
    John Wilding
    Diabetes Therapy, 2019, 10 : 1595 - 1622
12345